Honey bee as apitoxin, carries several active components, the most abundant of which is melittin, and the most biologically active are enzymes, particularly phospholipase A2. Bee venom is under laboratory and clinical research for its potential properties and uses in reducing risks for adverse events from bee venom therapy, rheumatoid arthritis, and use as an immunotherapy for protection against allergies from insect stings. Bee venom products are marketed in many countries, but, as of 2018, there are no approved clinical uses for these products which carry various warnings for potential allergic reactions. With an increased number of honey bees in a specific
Venom (comic book) abusing his father's body; he is eventually defeated and incarcerated by Venom. According to DCD, Remender's "Venom" #1 was the 128th-bestselling single issue of 2011 (based on an estimated 65,600 issues shipped). "Venom" #2 was number 389; sales dropped for each successive issue for the year, finishing at number 802 with "Venom" #11 (based on an estimated 28,700 issues shipped). "Venom" #22 (October 2012), Remender's final issue, sold an estimated 26,734 issues. The trade paperback "Venom Volume 1" ("Venom" #1-5) was the 134th-bestselling trade paperback of 2012, followed by "Circle of Four" at number 359 and "Savage Six" at number